Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
We have evaluated the efficacy of dapagliflozin in patients with type 1 diabetes mellitus (DM1) without adequate control. We expected that adding dapagliflozin to this population on top of their base treatment would lower their HbA1c levels. We conducted a pragmatic, open, 24-week study of treatment with 10 mg of oral dapagliflozin in patients with DM1 and chronic hyperglycemia. We evaluated glycemic control, lipid profile, weight, and insulin dose. Safety was assessed by adverse event reporting. Fasting glucose levels decreased from 176.42 ± 45.33 mg/dL to 139.67 ± 44.42 mg/dL (p = 0.05); although no significant valued was reached, postprandial glucose showed a decreased tendency from 230.25 ± 52.06 mg/dL to 193.83 ± 45.43 mg/dL (p = 0.08). The hemoglobin A1C (HbA1C) level decreased from 9.18 ± 1.02 (77 ± 11.1 mmol/mol) to 8.05 ± 1.09 % (64 ± 11.9 mmol/mol) (p = 0.0156); total cholesterol decreased from 299 ± 12 to 199 ± 7 mg/dL (p = 0.02); triglycerides decreased from 184 ± 15 to 160 ± 11 mg/dL (p = 0.0002), HDL-C decreased from 40 ± 17 to 42 ± 9 mg/dL (p = 0.54); and LDL-C decreased from 187 ± 19 to 170 ± 21 mg/dL (p = 0.049). No adverse events were reported. The beneficial effects of SGLT2 inhibitors on metabolic control and their safety after a 24-week open study demonstrate their potential indication as an adjunctive treatment with insulin in patients with DM1; however, long-term clinical trials should be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D. R., & Tsapas, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00007 · Cited by 911
Rosenstock, J., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-1380 · Cited by 664
Cherney, D. Z., Perkins, B. A., Soleymanlou, N., Har, R., Fagan, N., Johansen, O., Woerle, H.-J., von Eynatten, M., & Broedl, U. C. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-28 · Cited by 470
Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus
Fullerton, B., Jeitler, K., Seitz, M., Horvath, K., Berghold, A., & Siebenhofer, A. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009122.pub2 · Cited by 299 · cited 1×
“a search for other therapeutic options, like pramlintide or islets transplantation [1–3, 10–12].”
Background
Cited by
Handelsman, Y., Henry, R. R., Bloomgarden, Z. T., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Ferrannini, E., Fonseca, V. A., Garber, A. J., Grunberger, G., et al. (2016) · Endocrine Practice · doi:10.4158/ep161292.ps · Cited by 358
McCoy, R. G., Dykhoff, H. J., Sangaralingham, L., Ross, J. S., Karaca-Mandic, P., Montori, V. M., & Shah, N. D. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0213 · Cited by 122
Famulla, S., Pieber, T. R., Eilbracht, J., Neubacher, D., Soleymanlou, N., Woerle, H. J., Broedl, U. C., & Kaspers, S. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0261 · Cited by 53
El Masri, D., Ghosh, S., & Jaber, L. A. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.01.004 · Cited by 45
Patel, N. S., Van Name, M. A., Cengiz, E., Carria, L. R., Weinzimer, S. A., Tamborlane, W. V., & Sherr, J. L. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0267 · Cited by 30
Metadata
- Authors
- Tamez, H. E., Tamez, A. L., Garza, L. A., Hernandez, M. I., & Polanco, A. C.
- Venue
- Journal of Diabetes & Metabolic Disorders
- Published
- 2015-10-09
- Volume
- 14
- Issue
- 1
- Pages
- 78-78
- ISSN
- 2251-6581 (ISSN-L)
- OpenAlex
- W2119405541
- Cited by
- 34
- References
- 4
- FWCI
- 6.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus. https://app.cochat.ai/papers/10.1186/s40200-015-0210-x
- The paper
- Tamez, H. E., Tamez, A. L., Garza, L. A., Hernandez, M. I., & Polanco, A. C. (2015). Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus. Journal of Diabetes & Metabolic Disorders. https://doi.org/10.1186/s40200-015-0210-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.